AGENĀ – Agenus Inc.
Agenus Inc.AGEN
$3.11Name : Agenus Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $129,507,960.00
EPSttm : 2.05
Agenus Inc.
$3.11
0.96%$0.03
AGEN — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
14.19
Margin Of Safety %
Put/Call OI Ratio
0.24
EPS Next Q Diff
-0.12
EPS Last/This Y
0.5
EPS This/Next Y
-2.8
Price
3.11
Target Price
15.5
Analyst Recom
1
Performance Q
-7.72
Upside
598.1%
Beta
1.55
Ticker: AGEN
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-05-11 | AGEN | 3.26 | 0.15 | 1.32 | 10915 |
| 2026-05-12 | AGEN | 3.44 | 0.15 | 0.04 | 10952 |
| 2026-05-13 | AGEN | 3.46 | 0.15 | 0.36 | 11039 |
| 2026-05-14 | AGEN | 3.58 | 0.15 | 0.00 | 11141 |
| 2026-05-15 | AGEN | 3.58 | 0.15 | 0.03 | 11193 |
| 2026-05-18 | AGEN | 3.15 | 0.21 | 0.12 | 4687 |
| 2026-05-19 | AGEN | 3.1 | 0.21 | 0.61 | 5072 |
| 2026-05-20 | AGEN | 3.14 | 0.22 | 0.04 | 5222 |
| 2026-05-21 | AGEN | 3.16 | 0.22 | 0.11 | 5293 |
| 2026-05-22 | AGEN | 3.12 | 0.22 | 0.06 | 5404 |
| 2026-05-26 | AGEN | 3.33 | 0.21 | 0.18 | 5502 |
| 2026-05-27 | AGEN | 3.42 | 0.22 | 0.00 | 5621 |
| 2026-05-28 | AGEN | 3.4 | 0.21 | 0.23 | 5754 |
| 2026-05-29 | AGEN | 3.5 | 0.21 | 2.57 | 5904 |
| 2026-06-02 | AGEN | 3.38 | 0.22 | 0.07 | 5990 |
| 2026-06-03 | AGEN | 3.24 | 0.22 | 0.03 | 6026 |
| 2026-06-04 | AGEN | 3.39 | 0.22 | 0.13 | 6050 |
| 2026-06-05 | AGEN | 3.23 | 0.21 | 0.01 | 6178 |
| 2026-06-08 | AGEN | 3.14 | 0.21 | 0.72 | 6113 |
| 2026-06-09 | AGEN | 3.12 | 0.24 | 0.33 | 6436 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-05-11 | AGEN | 3.25 | 274.8 | 67.6 | 0.50 |
| 2026-05-12 | AGEN | 3.43 | 274.8 | 88.1 | 0.50 |
| 2026-05-13 | AGEN | 3.47 | 274.8 | 83.5 | 0.50 |
| 2026-05-14 | AGEN | 3.58 | 274.8 | -53.8 | 0.50 |
| 2026-05-15 | AGEN | 3.59 | 274.8 | -55.4 | 0.50 |
| 2026-05-18 | AGEN | 3.16 | 60.0 | -63.1 | 0.50 |
| 2026-05-19 | AGEN | 3.09 | 60.0 | -57.1 | 0.50 |
| 2026-05-20 | AGEN | 3.15 | 60.0 | -54.6 | 0.50 |
| 2026-05-21 | AGEN | 3.16 | 60.0 | -55.4 | 0.50 |
| 2026-05-22 | AGEN | 3.11 | 60.0 | -56.8 | 0.50 |
| 2026-05-26 | AGEN | 3.34 | 60.0 | -51.3 | 0.50 |
| 2026-05-27 | AGEN | 3.42 | 60.0 | -53.8 | 0.50 |
| 2026-05-28 | AGEN | 3.40 | 60.0 | -55.8 | 0.50 |
| 2026-05-29 | AGEN | 3.49 | 60.0 | -53.9 | 0.50 |
| 2026-06-01 | AGEN | 3.47 | 60.0 | -56.0 | 0.50 |
| 2026-06-02 | AGEN | 3.38 | 60.0 | -57.3 | 0.50 |
| 2026-06-03 | AGEN | 3.22 | 60.0 | -58.7 | 0.50 |
| 2026-06-04 | AGEN | 3.39 | 60.0 | -52.8 | 0.50 |
| 2026-06-05 | AGEN | 3.23 | 60.0 | -58.7 | 0.50 |
| 2026-06-08 | AGEN | 3.15 | 60.0 | -57.3 | 0.50 |
| 2026-06-09 | AGEN | 3.11 | 60.0 | -56.5 | 0.50 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-05-11 | AGEN | 0.00 | 3.38 | 11.85 |
| 2026-05-12 | AGEN | 0.00 | 3.38 | 12.70 |
| 2026-05-13 | AGEN | 0.00 | 3.38 | 12.70 |
| 2026-05-14 | AGEN | 0.00 | 3.38 | 11.71 |
| 2026-05-15 | AGEN | 0.00 | 3.38 | 11.71 |
| 2026-05-18 | AGEN | 0.00 | 4.07 | 11.71 |
| 2026-05-19 | AGEN | 0.00 | 4.07 | 11.71 |
| 2026-05-20 | AGEN | 0.00 | 4.07 | 11.71 |
| 2026-05-21 | AGEN | 0.00 | 4.07 | 11.71 |
| 2026-05-22 | AGEN | 0.00 | 4.07 | 11.71 |
| 2026-05-26 | AGEN | 0.00 | -2.20 | 11.71 |
| 2026-05-27 | AGEN | 0.00 | -2.20 | 11.71 |
| 2026-05-28 | AGEN | 0.00 | -2.20 | 14.19 |
| 2026-05-29 | AGEN | 0.00 | -2.20 | 14.19 |
| 2026-06-02 | AGEN | 0.00 | -2.72 | 14.19 |
| 2026-06-03 | AGEN | 0.00 | -2.72 | 14.19 |
| 2026-06-04 | AGEN | 0.00 | -2.72 | 14.19 |
| 2026-06-05 | AGEN | 0.00 | -2.72 | 14.19 |
| 2026-06-08 | AGEN | 0.00 | -2.72 | 14.19 |
| 2026-06-09 | AGEN | 0.00 | -2.72 | 14.19 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPSā
1.02
Avg. EPS Est. Current Quarter
-0.4
Avg. EPS Est. Next Quarter
0.9
Insider Transactions
Institutional Transactions
-2.72
Beta
1.55
Average Sales Estimate Current Quarter
34
Average Sales Estimate Next Quarter
34
Fair Value
Quality Score
43
Growth Score
32
Sentiment Score
18
Actual DrawDown %
97.7
Max Drawdown 5-Year %
-98.8
Target Price
15.5
P/E
1.86
Forward P/E
PEG
P/S
1.05
P/B
P/Free Cash Flow
EPS
1.67
Average EPS Est. Cur. Yā
0.5
EPS Next Y. (Est.)
-2.3
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
51.98
Relative Volume
0.61
Return on Equity vs Sector %
-56.6
Return on Equity vs Industry %
-40.4
EPS 1 7Days Diff
-1.5
EPS 1 30Days Diff
-1.46
EBIT Estimation
-56.5
ā
AGEN
Healthcare
$3.11
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
40.2
Range 1M
23.8%
Sup Dist
1.3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
141.3%
EPS NY
-122.9%
52W%
10%
Long-Term Value
Quality companies, undervalued
WEAK
š¢ BUY
+398.4% upside
Upside
+398.4%
Quality
43
Agenus Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 81
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFĆ TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
AGEN
Latest News
ā
Caricamento notizie per AGENā¦
stock quote shares AGENĀ – Agenus Inc. Stock Price stock today
news today AGENĀ – Agenus Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AGENĀ – Agenus Inc. yahoo finance google finance
stock history AGENĀ – Agenus Inc. invest stock market
stock prices AGEN premarket after hours
ticker AGEN fair value insiders trading